Grace Therapeutics, Inc.
GRCE· Nasdaq
GRCEGrace Therapeutics, Inc.
Filed Nov 16, 2020 · 10-Q · 47 days after period end · 0001171843-20-008002
| Metric | Q2 2021 | Q2 2020 |
|---|---|---|
| Net Income | -$6.15M | -$21.16M |
| EPS Diluted | -$0.52 | -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Sep 30, 2020 · filed Nov 16, 2020 · 47 d after period end
